Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSI-906 versus placebo in previously treated advanced adrenocortical carcinoma
NL-OMON36718Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in adrenal cancer (ACC) comparing OSI-906 with Placebo (2 arms). Primary endpoint: Overall survival. Started Jan 2010; status: active, not recruiting.
02
Drugs
linsitinib
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on NL-OMON36718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36718.